Delving into the Latest Updates on JADO Technologies GmbH with Synapse

Overview

The current study will investigate the effects of TF002 on cutaneous mastocytosis or cutaneous involvement of systemic mastocytosis as compared to clobetasol proprionate (positive control) and a general skin care product without active ingredient targeting mastocytosis (negative control) based on clinical effects on Darier´s signs and the histological evaluation of mast cell numbers in skin bioptic material.

Start Date01 Apr 2007

Sponsor / Collaborator

JADO Technologies GmbH

EUCTR2006-006704-10-DE / Not yet recruitingNot Applicable

Efficacy and Safety of Miltefosine in Cutaneous Mastocytosis - MICUMA

Start Date16 Mar 2007

Sponsor / Collaborator

JADO Technologies GmbH

100 Clinical Results associated with JADO Technologies GmbH

Login to view more data

0 Patents (Medical) associated with JADO Technologies GmbH

Login to view more data

2

Literatures (Medical) associated with JADO Technologies GmbH

01 Jul 2015·SLAS Discovery

A Combination of Screening and Computational Approaches for the Identification of Novel Compounds That Decrease Mast Cell Degranulation

Article

Author: Zerial, Marino ; Barsacchi, Rico ; McShane, Marisa P ; Giner, Angelika ; Bickle, Marc ; Meyenhofer, Felix ; Friedrichson, Tim

High-content screening of compound libraries poses various challenges in the early steps in drug discovery such as gaining insights into the mode of action of the selected compounds. Here, we addressed these challenges by integrating two biological screens through bioinformatics and computational analysis. We screened a small-molecule library enriched in amphiphilic compounds in a degranulation assay in rat basophilic leukemia 2H3 (RBL-2H3) cells. The same library was rescreened in a high-content image-based endocytosis assay in HeLa cells. This assay was previously applied to a genome-wide RNAi screen that produced quantitative multiparametric phenotypic profiles for genes that directly or indirectly affect endocytosis. By correlating the endocytic profiles of the compounds with the genome-wide siRNA profiles, we identified candidate pathways that may be inhibited by the compounds. Among these, we focused on the Akt pathway and validated its inhibition in HeLa and RBL-2H3 cells. We further showed that the compounds inhibited the translocation of the Akt-PH domain to the plasma membrane. The approach performed here can be used to integrate chemical and functional genomics screens for investigating the mechanism of action of compounds.

25 Apr 2008·ScienceQ1 · CROSS-FIELD

Efficient Inhibition of the Alzheimer's Disease β-Secretase by Membrane Targeting

Q1 · CROSS-FIELD

Article

Author: Simons, Kai ; Weidlich, Sebastian ; Schroeder, Cornelia ; Schulz, Jörg B. ; Ries, Jonas ; Jennings, Gary ; Simons, Mikael ; Knölker, Hans-Joachim ; Braxmeier, Tobias ; Schlechtingen, Georg ; Schneider, Anja ; Rajendran, Lawrence ; Schwille, Petra

β-Secretase plays a critical role in β-amyloid formation and thus provides a therapeutic target for Alzheimer's disease. Inhibitor design has usually focused on active-site binding, neglecting the subcellular localization of active enzyme. We have addressed this issue by synthesizing a membrane-anchored version of a β-secretase transition-state inhibitor by linking it to a sterol moiety. Thus, we targeted the inhibitor to active β-secretase found in endosomes and also reduced the dimensionality of the inhibitor, increasing its local membrane concentration. This inhibitor reduced enzyme activity much more efficiently than did the free inhibitor in cultured cells and in vivo. In addition to effectively targeting β-secretase, this strategy could also be used in designing potent drugs against other membrane protein targets.

1

News (Medical) associated with JADO Technologies GmbH

05 Sep 2007

·www.biospace.com

JADO Technologies Appoints New CEO

JADO Technologies, the leading developer of novel cell membrane-targeted drugs, today announced the appointment of Charl van Zyl as its new Chief Executive Officer. Charl van Zyl will take over from Dr. Gary Jennings, cofounder and former CEO/CSO, who will continue as Chief Scientific Officer.

100 Deals associated with JADO Technologies GmbH

Login to view more data

100 Translational Medicine associated with JADO Technologies GmbH

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 20 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

4

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

J-607Y	Inflammation More	Pending
TF 2-targeted cancer therapy(Immunomedics, Inc.) ( CEACAM5 x Histamine succinyl glycine )	Cutaneous Mastocytosis More	Pending
J-555Y	Urticaria More	Pending
J-775Y	Psoriasis More	Pending